SCHEMBL9905744

SCHEMBL9905744

CC1OCc2cccc(Oc3ccc([N+](=O)[O-])cn3)c21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPB1 P04792 2/20 0.47
MAPT P10636 11/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
PABPC1 P11940 1/20 0.39
BLM P54132 1/20 0.39
MAPK1 P28482 2/20 0.39
L3MBTL1 Q9Y468 3/20 0.38
GAA P10253 2/20 0.38
LMNA P02545 5/20 0.38
ALDH1A1 P00352 4/20 0.38
RGS12 O14924 1/20 0.38
APOBEC3A P31941 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
KDM4E B2RXH2 2/20 0.38
RAB9A P51151 1/20 0.38
HTT P42858 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9905753 0.86 HSPB1 (0.45) HSPB1MAPTNPSR1MEN1KMT2A
SCHEMBL9905746 0.80 KEAP1 (0.51) MEN1KMT2AALDH1A1KDM4ERAB9A
SCHEMBL9900943 0.76 HSPB1 (0.46) HSPB1MAPTNPSR1MEN1KMT2A
SCHEMBL9900322 0.75 HSPB1 (0.46) HSPB1MAPTNPSR1MEN1KMT2A
SCHEMBL6178485 0.73 HSPB1 (0.52) HSPB1MAPTNPSR1MEN1KMT2A
SCHEMBL6181901 0.73 HSPB1 (0.52) HSPB1MAPTNPSR1MEN1KMT2A
SCHEMBL9924209 0.73 XIAP (0.40) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL9904662 0.72 HSPB1 (0.46) HSPB1MAPTNPSR1MEN1KMT2A
SCHEMBL9923841 0.72 HSPB1 (0.44) HSPB1MAPTNPSR1MEN1KMT2A
SCHEMBL1978695 0.72 KEAP1 (0.59) HSPB1MAPTNPSR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 US disclosed
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 US disclosed
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2020-11-19 US disclosed
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2020-11-19 US disclosed
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2019-06-27 US disclosed
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2019-06-27 US disclosed
US-9346790-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-05-24 US disclosed
US-9346790-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-05-24 US disclosed
EP-2649066-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2015-10-21 EP disclosed
EP-2649066-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2015-10-21 EP disclosed
EP-2649066-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS Autifony Therapeutics Limited (GB) 2013-10-16 EP disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 US disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 WO disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 HSPB1 1810/4885MAPT 3926/4885NPSR1 1399/4885
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 HSPB1 1810/4885MAPT 3926/4885NPSR1 1399/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 HSPB1 1810/4885MAPT 3926/4885NPSR1 1399/4885
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 HSPB1 1810/4885MAPT 3926/4885NPSR1 1399/4885
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 HSPB1 1929/4885MAPT 3971/4885NPSR1 1433/4885
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 HSPB1 1810/4885MAPT 3926/4885NPSR1 1399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.